Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1998-12-18
2002-10-29
Caputa, Anthony C. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023500, C514S002600, C436S064000
Reexamination Certificate
active
06472508
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a novel human tumor suppressor and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and autoimmune diseases.
BACKGROUND OF THE INVENTION
When tumorigenic and non-tumorigenic cells are fused in culture, the resulting hybrid cells are usually non-tumorigenic. Loss of tumorigenicity is attributed to heritable factors within the non-tumorigenic cell which suppress tumor development. Several tumor suppressors including the retinoblastoma gene and p53 have been characterized and are of great interest to researchers and clinicians seeking to investigate and control cancer growth.
Both the retinoblastoma gene and p53 have become candidates for the development of cancer therapeutics (Knudson, A. G. (1993) Proc. Natl. Acad. Sci. 90:10914-21; Antelman, D. et al. (1995) Oncogene 10: 697-704; and Hamada, K. et al. (1996) Cancer Res. 56: 3047-54).
One of the genes which suppresses tumorigenesis, tsg101, was recently identified in mouse (Li, L. and S. N. Cohen (1996) Cell 85:319-329). Antisense RNA was used to disrupt transcribed genes throughout the genome of mouse 3T3 fibroblasts. Homozygous functional disruption caused oncogenesis, and the oncogenic cells, in turn, produced metastatic tumors in nude mice. Removal of the transactivating RNA allowed Li and Cohen (supra) to study and characterize genes with tumor suppressor activity.
Tsg101 was identified using this methodology and cloned from a mouse NIH 3T3 cell cDNA library. The predicted protein has 381 amino acids; an alpha-helix domain which has identity with cc2; a stathmin interaction domain; a proline-rich region which precedes a leucine zipper motif; a zinc finger signature (residues 73-83); seven potential protein kinase C phosphorylation sites (11, 38, 85, 88, 215, 225, 357); five potential case in kinase II phosphorylation sites (38, 210, 249, 265, 290); two potential N myristoylation sites (55 and 156); and three potential N glycosylation sites (44, 150, 297). Oncogenesis was observed when the activity of tsg101 was knocked out by introducing a synthesized, tsg101 antisense RNA into native NIH 3T3 cells.
The zinc finger and leucine zipper motifs of tsg101 may allow the protein to function as a transcription factor; however, Li and Cohen (supra) suggest, tsg101 may interact with stathmin (oncogene 18), a cytosolic phosphoprotein that functions in cell growth and differentiation. Stathmin is known to be phosphorylated in response to growth and differentiation factors during cell cycle transitions, embryonic development, T cell activation, and tissue regeneration. Stathmin expression increases in acute leukemia, highly malignant lymphoma and neuroblastoma and in cells overexpressing tsg101 (Li and Cohen, supra).
Mutations in tumor suppressor genes are a common feature of many cancers and often appear to affect a critical step in the pathogenesis and progression of tumors. Accordingly, Chang, F. et al. (1995; J. Clin. Oncol. 13: 1009-1022) suggest that it may be possible to use either the gene or an antibody to the expressed protein 1) to screen patients at increased risk for cancer, 2) to aid in diagnosis made by traditional methods, and 3) to assess the prognosis of individual cancer patients. In addition, Hamada et al. (supra) are investigating the introduction of p53 into cervical cancer cells via an adenoviral vector as an experimental therapy for cervical cancer.
Polynucleotides and polypeptides related to tsg101 satisfy a need in the art by providing compositions useful in the diagnosis, prevention, and treatment of cancer and autoimmune diseases.
SUMMARY OF THE INVENTION
The present invention features a novel human tumor suppressor, hereinafter designated NHTS, and characterized as having similarity to tumor suppressor gene 101 (tsg101) from mouse.
Accordingly, the invention features a substantially purified NHTS having the amino acid sequence shown in SEQ ID NO:1.
One aspect of the invention features isolated and substantially purified polynucleotides that encode NHTS. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.
The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.
The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode NHTS. The present invention also features antibodies which bind specifically to NHTS, and pharmaceutical compositions comprising substantially purified NHTS. The invention also features the use of agonists and antagonists of NHTS.
REFERENCES:
patent: 5679523 (1997-10-01), Li et al.
Bowie et al (Science, 1990, 257:1306-1310).*
Burgess et al ( J of Cell Bio. 111:2129-2138, 1990).*
Lazar et al (Molecular and Cellualar Biology, 1988, 8:1247-1252).*
Greenspan et al. (Nature Biotechnology 7:936-937 (1999).*
Gura et al. (Science, v278, 1997, pp. 1041-1042.*
Bork, Genome Research, 2000, 10:398-400.*
Scott et al., Nature Genetics, 1999, 21:440-443.*
Hamada, K., et al., “Adenovirus-mediated Transfer of a Wild-Type p53 Gene and Induction of Apoptosis in Cervical Cancer”,Cancer Research, 56: 3047-3054 (1996).
Li, L., et al., “tsg 101: a Novel Tumor Susceptibility Gene Isolated by Controlled Homozygous Functional Knockout of Allelic Loci in Mammalian Cells”,Cell, 85: 319-329 (1996).
Chang, F., et al., “Implications of the p53 Tumor-Suppressor Gene in Clinical Oncology”,Journal of Clinical Oncology, 13: 1009-1022 (1995).
Li, L., et al., (GI 1330329 GenBank Sequence Database (Accession U52945), National Center for Biotechnology Information: National Library of Medicine, Bethesda, Maryland 2084.
Li, L., et al., (GI 1330330) GenBank Sequence Database (Accession U52945), National Center for Biotechnology Information: National Library of Medicine, Bethesda, Maryland 2084.
Li, L., et al., “The TSG101 Tumor Susceptibility Gene is Located in Chromosome 11 Band p15 and is Mutated in Human Breast Cancer”,Cell, 88: 143-154 (1997).
Li, L., et al., (GI 1772663) GenBank Sequence Database (Accession U82130), National Center for Biotechnology Information: National Library of Medicine, Bethesda, Maryland 2084.
Li, L., et al., (GI 1772664) GenBank Sequence Database (Accession U82130), National Center for Biotechnology Information: National Library of Medicine, Bethesda, Maryland 2084.
Brie Sam La
Goli Surya K.
Caputa Anthony C.
Incyte Genomics Inc.
Incyte Genomics, Inc.
Nickol Gary B.
LandOfFree
Human tumor suppressor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human tumor suppressor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human tumor suppressor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2973582